Skip to main content

Mineralys Therapeutics, Inc Investor Event Transcript, Nov 12, 2026

Mineralys Therapeutics, Inc. (MLYS)

Mineralis Therapeutics tracks a December 22nd PDUFA date for lorunderstat and readiness for a 2027 launch. It stated $625 million in capital, including a $500 million secured facility with $100 million drawn. AI summary

Investor Event Transcript 2026-11-12 For: 2026-12-31
Added on November 12, 2026

Conference Transcript - MLYS 2026-11-12

Operator

Okay. Good morning, everyone, and welcome to the Mineralis Therapeutics Session. I'm happy to have John Conkelton, CEO of Mineralis, with us this morning. And as you know, Mineralis is developing a new class or has developed a new class of drugs, aldosterone synthase inhibitors, for uncontrolled and resistant hypertension. And, John, why don't you give a quick overview and the lay of the land, and we'll just launch into questions.

John Conkelton, CEO

Yeah, happy to do it, and good to see you, Annabelle, and thank you again to the Stiefel team. Always enjoy the conference and the opportunity to talk about mineralis. As you said, we're thrilled to be a part of a new class, aldosterone synthase inhibitors. As Annabelle knows, I started my career as a sales rep in this space, and I've seen how transformative new treatments can be, Given the fact that about half of the treated patients in the United States cannot get to goal with currently available treatments, I think having innovations like aldosterone synthase inhibitors and lorunderstat are really critical. We've spent the last five-plus years, I think, building a very robust, diverse data set that went into our NDA about a year ago. We are progressing towards our PDUFA date, December 22nd of this year, and have progressively built out a readiness to ensure that we have a successful launch going into 2027.

Annabelle, Analyst — Stiefel

Great. So let's talk about that PDUFA date. December 22nd is obviously approaching very Very quickly, and you have a... I would say a pretty impressive large trial package. So how are you seeking to leverage that wealth of data that you have to support a differentiated label? And can you potentially get a differentiated label rather than just like standard, you know, uncontrolled resistant hypertension?

John Conkelton, CEO

Yeah, so the Bidoof remains on track. I think if I think about the label, there are going to be some similarities and there'll be some differences relative to what Baxter Stag got this summer. The similarities are going to be the indication. And it's for the treatment of inadequately controlled hypertension on top of background medications. There's also going to be a statement about reduced blood pressure reduces the risk of stroke, MI, and cardiovascular disease. That's based on FDA guidance from 2012, and so that'll look similar. Where the differences obviously come is in the body of the label, certainly Section 14. We really efforted to create a data set that reflects the population that physicians are treating when they're treating hypertension. There's a lot of variety, and there's a variety in gender, race, age, obviously, but there's also a lot of overlapping comorbidities, and so the work that we did with our Explore programs looking at the benefit of lorunderstat in patients with comorbid CKD, the OSA study, and comorbid OSA, obesity, how much of that will be reflected in the label will be, you know, known by December 22nd. But I think, fundamentally, having that wealth of data is going to be important for the medical community to know how to incorporate lorunderstat into their treatment paradigm. And we have different vectors to do that, right? We have the promotional team, sales and marketing. We have med affairs to disseminate publications and make sure that KOL interactions, they understand not only the data within the label, but just our broader data set and how to appropriately use lorunderstat.

Annabelle, Analyst — Stiefel

And when you think about the package they have in the population that you've studied, where do you think physicians are going to be most comfortable using the drug first?

John Conkelton, CEO

I think so we've built a data set looking at patients failing two or more meds. So that's third line uncontrolled and fourth line resistant. I think the low hanging fruit will be the fourth line. So the resistant hypertension population. It doesn't mean that we won't be promoting for both, but I think based on initial trial by physicians, initial access, fourth line is going to be the predominant area. As far as patient subtypes within that, again, I think that's where the diversity of the patient populations that we have for fourth lane can speak to it very broadly. Case in point, black African Americans are... We're probably the highest risk population as far as most difficult to get to their respective goals. We had 29 and 53 percent of our two pivotal studies were black or African-American, so physicians don't have to presume that the drug is going to work across race. We can show them the data and say Larendrostat works equally well, and that's important because there's variable response based on ethnicity. Having data, not only the Explore CKD study, but LaunchHTN, we presented a subset analysis of those patients with CKD. So really robust and meaningful reduction in blood pressure, reduction in UACR. So it's these pockets of patients, and again, by physician type, primary care, cardiology, nephrology. So I think we've got really exquisite data sets to really speak to the specific patients they're seeing.

Annabelle, Analyst — Stiefel

And can you just remind us what Baxfendi has as far as where they can position the drug in the marketplace?

John Conkelton, CEO

So Baxfendi, similar construct in... The number of background meds. So they looked at patients failing on two or more. So similar in that regard, so third line and fourth line is where they can position it. I think we've got a little bit more diversity within our studies, both on gender and on race. And I think just what's been published today at a broader population or broader background as far as comorbidities, things like OSA and obesity.

Annabelle, Analyst — Stiefel

Great. Maybe you can talk to us before we get into how you're going to launch this drug. Can you provide any color from any of the mid to late cycle stage meetings that you had with FDA, like any further requests post the 120-day safety update? What type of post-marketing requests might they make of you or have you do?

John Conkelton, CEO

Yeah, so I'll reiterate, December 22nd is where we're tracking to. I would characterize, because we haven't really gotten into the details and specifics of where we are, but I would characterize it as kind of normal course. Again, you made the point. I think we have a very meaningful and robust data package that we were able to put into the NDA, very well characterized, and including Explore CKD in the lower EGFR population, giving a full picture of lorunder stat across the spectrum of hypertension. So I feel very confident on that December 22nd date. Okay.

Annabelle, Analyst — Stiefel

So, obviously, Baxter stat is launched already. Max? Baxter stat, Baxpendi. But I guess without head-to-head data or cross-trial comparisons between the two, how are you preparing to speak to physicians about, you know, maybe even the payers to evaluate Larendra Stratt relative to what's available to them right now? Do you think that there's something that clearly distinguishes the two outside of just data? And are you expecting counter-detailing or are you just launching? I plan to launch Loranderstat. Hopefully, you get an easier name to say. It's like killing me. You want to buy an R. Is there anything that you're going to be, are you just launching the drug on its own merits, or are you going to start counter-detailing? How are you going to position it?

John Conkelton, CEO

Yeah, it's a great question because as I meet with investors, I get asked, juxtapose Loranderstat And I think that's missing the bigger boat. I think the real interesting opportunity is ASI relative to what's available right now, and why that's important is there's a lot of meta-analysis that would say when you add a third or a fourth-line agent of what's currently available of these generics, you get maybe five to seven millimeter mercury reduction, and I think that's why the medical community is really excited about the ASI class, is because you're seeing really There are really meaningful reductions in these patients that cannot get to go on two or more meds, so whether they're uncontrolled or resistant, you know, in the case of Lerunderstat from LaunchHTN, you're seeing a 19-millimeter mercury absolute change in about 11.7 placebo-adjustin. I mean, that is, that's not currently available to physicians right now. An aldosterone-directed treatment that patients can tolerate, that physicians want to prescribe. And I think my view, and I think there's literature that supports this, when you get a patient that's not a goal on two, certainly three, and beyond meds, it's likely aldosterone that is kind of still that final culprit that's really getting in the way of patients getting the goal. And I think that's validated by the kind of data that we've seen. And so for me, job one, from a communication standpoint, is not to go Baxter-Stattler-Under-Statt back and forth. It's to talk about... Why choose an ASI over an alpha blocker, a beta blocker, a calcium channel blocker, an MRA? And then once that's done, then yes, you know, what are the similarities, what are the differences between Lorander stat and Baxter stat? And that's where I feel very confident that once the community sees that ASI is the way to go, that then we'll make the comparison between the two. And I think we've got a very good case that when a physician has chosen an ASI, that Lorander stat is the way they're going to want to go.

Annabelle, Analyst — Stiefel

I do physicians, um... Do you know which patient, does the patient present in a certain way other than uncontrolled or resistant hypertension? Is it very easy to clinically diagnose which patient would be responsive to an ASI over something else?

John Conkelton, CEO

You know, it's a really fair question because right now it's... There are no markers. So in other words, right now, if you were on three meds and went in and your blood pressure was still not controlled, there aren't markers that would guide and direct what a physician should choose. So it's a little bit of just trial and error going forward. In the case of the aldosterone synthase inhibitors, we're seeing the medical community progressively talk about getting aldosterone measurements, getting renin measurements, doing an aldosterone-renin ratio. But I think fundamentally given, like the case of Loranderstatt, you take Loranderstatt, within two weeks, you're going to... Know if your patient's going to respond or not. And then that's durable. We showed it in Chicago after 48 weeks. So I don't know if, even though the medical community's thinking about markers more, I don't think it's going to be necessary. I don't think it's a practice that is going to be incorporated immediately in due course. I think where the fit is going to be is if a physician has a patient on three meds, they're still not at goal, and they see certain characteristics that they feel matches up to the data that we have. So, again, Black African-American patient, maybe a female patient, if they have CKD or if they have OSA, that may be the initial trigger. Now, we know Larendra Stout works black or white, male or female, but there may be certain pockets that trigger for them and they get that experience. And so that's where I think there's, um, A real opportunity to convince them that aldosterone's probably the problem. ASI is this nice new innovation that's going to help you get a significant portion of them to goal, and Lerunderstat has the most, you know, breadth and diversity of a data set to really inform how they would prescribe it.

Annabelle, Analyst — Stiefel

Where are you in terms of talking to, in terms of altering the guidelines?

John Conkelton, CEO

Yeah, we've, we've, so there's, there's multiple guidelines out there and directives and things like that. So we've identified all the different KOLs that are on the committees, had good dialogues with them, you know, obviously they've. They want to kind of be a little bit standoffish and have independence, and I appreciate that, but we make sure that they've got the information, they've got all of our studies, they're up to date on most recent publications for the data that we have. I think we're seeing progressively some of the guidelines come out. My expectation is the initial guidance will be fourth line and probably on par and parity to MRAs, and so it's ASI MRA as suggested option at fourth line. I think as data continues to progress, as experience progresses, we may see that move sooner within the treatment paradigm third line. And the guidelines are helpful. They're informative, but they're not... They're adhered to strictly by either physicians and or payers. So I think they're, as stated, they're a guideline. They help inform. But just because an ASI is viewed as fourth line doesn't mean physicians are going to trial that third line, and it doesn't, ultimately, isn't going to restrict us from third line from an access standpoint. Okay.

Annabelle, Analyst — Stiefel

You did mention something where people have asked a lot of questions around. So if the guidelines are that MRAs and ASIs are at the same sort of level, how are the payers approaching step-throughs of the MRAs? And we know they're not ideal for this condition. I know the patients can't stay on it that long because of tolerability. But, like, how might that affect your ability to come before or at the same time as MRAs?

John Conkelton, CEO

Yeah, the, I think that's... One of the things that's been really validating about the BaxterStat launch.

Annabelle, Analyst — Stiefel

Yeah, and I was just going to ask you, what is Backspend even experiencing there?

John Conkelton, CEO

Well, and that's the great thing because, you know.

Annabelle, Analyst — Stiefel

They're blazing the trail for you.

John Conkelton, CEO

Exactly, and, you know, the good news is we've had our account management team in place since Q1, so we're getting this real-time feedback from these payers as well in the dialogues about Lerunderstat, but we're also seeing in real-time what's going on with BaxterStat. And the bottom line is, it is not, in the vast majority of cases, a step through MRA. The utilization management is actually fairly straightforward, and by plan it varies, but it's a look back in their electronic medical record, and do they have a history of having uncontrolled blood pressure, and are they on either two or three, in most cases, three medicines, and it's a basket approach. In other words, it doesn't matter what those three are. It can be an MRA. It cannot be an MRA. As long as they have been on three or more meds and are failing to get to goal over a certain look-back period, then that becomes the step at it, and that's validating because that's what the research has told us over the last five years as we've gone out and talked to payers. They understand, particularly when you get into resistant hypertension, these are the more obviously at-risk patients. They've had uncontrolled hypertension for a longer period of time. They're the ones that are at the risk of stroke, heart attack, progressive kidney disease, and so they become more relevant from an economic health standpoint for these payers. And they also, certainly the pharmacy directors, understand the issues and challenges with spironolactin and know it is not a de facto choice to force patients to go through if they want to go to an ASI. And so we're seeing that play out in real time right now.

Annabelle, Analyst — Stiefel

Okay. I guess to that point, I guess ICER had come out with an October 29th panel and found that it, that... ASIs have similar blood pressure effects as spironolactone or eplerinone or maybe even amlodipine, and so are there any, again, you mentioned that. Probably not. Payers understand that, but, you know, ICER is not putting out—is a potential recommendation by ICER saying that they're not seeing any greater benefit from ASI is going to affect anything that happens from a reimbursement perspective for any of the ASIs?

John Conkelton, CEO

Yeah, from my vantage point, no. I appreciate ICER's remit. We have some fundamental— Disagreements in populations. They looked at methodology that was used. You know, comparing to agents that just aren't used doesn't make sense to me. I'm sorry. Because they looked at spironolactylnoplarinone and ameloride, so a sodium channel inhibitor. They're just so rarely used. They're saved for later in line. They should, frankly, any aldosterone-directed treatment should be used much earlier because we know the prevalence of dysregulated or elevated aldosterone. So while I appreciate their remit, I think fundamentally we view the methodology behind that differently. And I think we're seeing that with the payers as well. They appreciate the innovation of an aldosterone-directed treatment that physicians want to use and patients want to stay on. And so it's a part of the ecosystem, but I don't see it as a hindrance relative to the value of the data we have and the need that's in the marketplace.

Annabelle, Analyst — Stiefel

So I guess payers do not feel compelled to use the ICER. Data at all. I mean, ICER puts out a recommendation, but no one really needs to use them.

John Conkelton, CEO

I don't want to say nobody uses it. It probably becomes part of the calculus, but in our discussions, it's not a barrier.

Annabelle, Analyst — Stiefel

One more, I guess, bit about the data that you have. So how do you think that you can leverage the Explore HTN and the... I'm sorry, explore CKD. I can't remember the name of the address. You know, OSA, explore, all of those, CKD, OSA. How might that resonate with physicians? How do you plan on leveraging that data?

John Conkelton, CEO

Yeah, some of it was part of, so some of the EXPLORE studies and the data from that were part of the submission, so EXPLORE CKD was. EXPLORE OSA was not because that study read out subsequent to the NDA. So some of it is within the, Published medicine realm, so we've got a really strong medical affairs team, both in the field interacting with national and regional KOLs, but it's also, frankly, part of our publication plan, which is becoming progressively more important as you think about things like open evidence, doximity, all of these AI aggregators of information they're pulling from posters, abstracts, presentations, and manuscripts. And so getting this information out that, again, speaks to... Where the field's going, and there was a presentation, I missed it, unfortunately, Monday in Chicago at the AHA, but it's talking about the treatment of CKM, and it's this progressive shift. It's been interesting over the six years I've been involved with mineralis that it's not just hypertension, it's not just diabetes, it's not just CKD, but these things are all interrelated.

Annabelle, Analyst — Stiefel

What does the M stand for?

John Conkelton, CEO

Um, so... Cardiac, kidney, metabolic. So it's everything, and I'm surprised that it's taken this long to get this energy behind it. Maybe it's some of the innovations that are coming now between the SGLT2 several years ago, the GLP-1s or anti-obesity treatments, ASIs, but I think you're progressively seeing physicians trying to think a bit more holistically about those CKM conditions. And so... We kind of saw that writing on the wall and wanted to progressively build out a robust data set. So in the case of Explore CKD, that we may see in the label. There were two places that that was really informative. One was special populations, so experience. With Lorander stat down to EGFR of 30. We know Baxter stat's label says it's experienced down to EGFR of 45. Our two pivotal studies looked at EGFR of 45, but explore went down to 30. And so being able to go to a nephrologist and say, if you've got a uncontrolled resistant hypertension patient with CKD down to EGFR of 30, here's data that shows you what you can expect with Lorander stat. Not only on kidney function, on blood pressure, but also safety and electrolytes, because that's an important consideration. Explore OSA is not on the label, per se, but again, that was a severely... Severely affected OSA population, AHI score of 48, very obese, BMI of 37, and just in a four-week period of time, saw an 11 millimeter mercury drop in systolic blood pressure. We didn't see an effect on OSA, unfortunately, with AHI, but we clearly saw an effect on blood pressure. And so again, it's kind of meeting the doctors where they are because these doctors are dealing with hypertension patients that are complex.

Annabelle, Analyst — Stiefel

Okay. So maybe we can get into the launch expectations. How should investors think about, let's just say, 2027 launch costs first, because I'm sure the trajectory is not something you can speak to at this point, and who you're targeting first? I imagine it would be cardiologists, but maybe you can segment the cardiologists for us a little bit.

John Conkelton, CEO

Yeah, maybe let me take a step back. So we brought in our chief commercial officer in April of 25. He built out his leadership team in the summer of 25. So we've been progressively building towards launch readiness. In Q1, as I noted, we put our account team in place, so calling on PBMs and insurers, making them aware of our data package and our plans coming forward. In Q2, we upsized our medical field team so that we could get deeper into the KOL aspects, and then, as we noted in our earnings call, last Wednesday, our sales team is fully in place. So at this point, they're getting trained, they're getting out into their geographies, acclimating, meeting their customers, ensuring or confirming the targets that we've identified. So those targets are really... A mix of predominantly three specialists, primary care, high-volume primary care, cardiologist, and nephrologist. We have, from the last several years, really been focused on the 45,000 to 50,000 doctors that control about 40% to 50% of third-line or later prescribing. I know people think about hypertension, they think about you need tons of reps for all of these doctors, But when you're getting to the lateral lines of treatment, it really begins to narrow nicely. And those 45,000 to 50,000 doctors only control a high percent of the prescribing, but they influence the other part of that. And so this build-out that we've done from account management to ensure access to our MSLs, to our sales team, is really predicated on let's target those high-volume prescribers out of the gate. And it's been interesting to see the Baxter stat launch and the data they have as far as source of scripts because it's a little over half primary care. It's probably about 20-25% cards and 20% nephrologists. And the nephrologists were a little bit of a surprise. We did not see that. Prior to the Baxter stat launch in the kind of nationwide data for third-line or greater prescribers, the NEFs did not show up as much, but they're obviously embracing the ASI class, which I think is a positive for us, given the kind of data that we have.

Annabelle, Analyst — Stiefel

Right, and it's probably also because of AstraZeneca's presence in the nephrology area.

John Conkelton, CEO

Possibly, but I mean, yeah, yeah, maybe.

Annabelle, Analyst — Stiefel

And so I guess I know a few investors kind of looked at the Baxter Stat launch and saw their result from this quarter or this past quarter and got a little bit nervous. What do you think is happening? What dynamics are you hearing? Is it fair to even look at their sales at this point and draw any conclusions? Shouldn't they just be looking at the scripts?

John Conkelton, CEO

To me, right now, it's about scripts. And the scripts that, you know, looking at the same data that you're looking at, to me, is validating. I think it's promising. It's showing that there's market access there. It's showing that there's demand there. And we also don't have visibility to... Everything, right? There may be patients in the hub. There may be free goods patients that aren't showing up. So just the Rx's themselves, I think, are very promising. So that's kind of where my focus is, to look at revenues in early quarters. There's just so many vagaries in there and how they account for free goods and bridge and coupons. It's just hard to tell.

Annabelle, Analyst — Stiefel

What kind of specialty pharmacies or hubs are you creating for patients to facilitate adoption?

John Conkelton, CEO

Yeah, that's a really critical part. As we do market research with physicians, I mean, they absolutely respond very favorably to the efficacy, the safety of this molecule. Their big question is, are it access? Is it going to be easy to access? This won't be through specialty. This is, it's small molecule through retail, but we have hired just a top-notch team to basically help build out our PSP hub system, and we've got great partners that we've identified throughout this value chain that makes it very easy for a physician, once they've decided to prescribe or understand, and a patient they've decided they want to take it, to get access to it, and so that's really a double-pronged... Strategy of how do we make it easy for the office? So take that burden off of them. And then how do we make it seamless and transparent for the patient and build that out? And so that's another component of the launch readiness that we've got in place.

Annabelle, Analyst — Stiefel

Are you creating your own hubs or possibly leveraging other pharmacy fulfillment centers or prescription fulfillment centers?

John Conkelton, CEO

We've got our internal team leading that, but it is leveraging existing infrastructures. There's a lot of partners within that, and where I feel good is just how we'll make that seamlessly all fit together.

Annabelle, Analyst — Stiefel

Okay, great. And then I guess as we're coming to the tail end of this, maybe you can talk about... The cash that you have right now, you said, I think, on the call that it was sufficient to fund you through 2028, which is part of, you know, I guess the beginning of the launch. You also have, I believe, a $500 million secured loan. So, you know, what are the conditions where you'd be drawing on that loan rather than potentially going back to the markets for additional cash?

John Conkelton, CEO

Yeah, so as you noted, we stated in our Q3 call, $625 million in capital right now. We did the facility this summer, $500 million, pulled $100 at the close. Upon approval, we'll pull another $150 million. That leaves another $250 million that really kind of gives us flexibility. It's at our discretion. Should we need it? Should we feel that we want it to give us some flexibility from a capital standpoint? We feel fairly comfortable, obviously, getting into 28, but that we've got the cash and access to capital on hand to get us through the launch of Lerunderstat. And so, you know, that is inclusive of what we did this summer. I think it was really important what we did with buying back the royalties.

Annabelle, Analyst — Stiefel

I was just going to ask you about the royalties and what the rationale was behind them.

John Conkelton, CEO

Yeah, no matter, A, it was opportunistic. We found out that because Bain had bought Tanabe, that Bain was looking to monetize the royalties. And It was happening imminently, so it was either going to be us or somebody else, and we said we cannot let these go by if we think we can get them for quite the deal, and I think fundamentally we did, and no matter how, whatever scenario we play out, so if it's us launching on our own, if it's with a partner, if it's an M&A, that investment made a ton of sense. As we go into the commercialization, we'll understand, I'm thrilled. I mean, the royalties weren't onerous, but they were meaningful, 6% to 10%. That now flows to the bottom line for us. That gives us strategic flexibility as we think about access, as we think about price points. So, you know, between making that move, I think that clearly drew value for us. And then the cash that we have on hand, the capital we have access to, I feel very comfortable going into the launch year of 2027, that we're going to be not only ready for launch, but have a very meaningful launch and have a significant share of voice relative to AstraZeneca.

Annabelle, Analyst — Stiefel

Okay. That's all the time we have, so thank you.

John Conkelton, CEO

Yeah, thank you. Appreciate the opportunity.